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Abstract: It has become very clear that a single molecular event is inadequate to accurately predict the biology (or 
pathophysiology) of cancer. Furthermore, using any single molecular event as a biomarker for the early detection of malig-
nancy may not comprehensively identify the majority of individuals with that disease. Therefore, the fact that technologies 
have arisen that can simultaneously detect several, possibly hundreds, of biomarkers has propelled the ﬁ  eld towards the 
development of multianalyte-based in vitro diagnostic early detection tests for cancer using body ﬂ  uids such as serum, 
plasma, sputum, saliva, or urine. These multianalyte tests may be based on the detection of serum autoantibodies to tumor 
antigens, the presence of cancer-related proteins in serum, or the presence of tumor-speciﬁ  c genomic changes that appear 
in plasma as free DNA. The implementation of non-invasive diagnostic approaches to detect early stage cancer may provide 
the physician with evidence of cancer, but the question arises as to how the information will affect the pathway of clinical 
intervention. The conﬁ  rmation of a positive result from an in vitro diagnostic cancer test may involve relatively invasive 
procedures to establish a true cancer diagnosis. If in vitro diagnostic tests are proven to be both speciﬁ  c, i.e. rarely produce 
false positive results due to unrelated conditions, and sufﬁ  ciently sensitive, i.e. rarely produce false negative results, then 
such screening tests offer the potential for early detection and personalized therapeutics using multiple disease-related 
targets with convenient and non-invasive means. Here we discuss the technical and regulatory barriers inherent in development 
of clinical multianalyte biomarker assays. 
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Introduction
The prospects of diagnostic tests for the early detection of cancer using genomic and proteomic 
technologies have opened a Pandora’s Box of questions on the steps in development of clinical tests. 
Formatting the reagents into a conﬁ  guration that is amenable to a clinical laboratory is a rather daunting 
barrier to a successful clinical test. Even the development of a generic approach to measure 20–100 
analytes will require solutions to some unique optimization challenges. Formatting the complete 
diagnostic test will be more than 20 to 100 times the cost of formatting a single test. A major barrier in 
multianalyte diagnostics will be the large number of controls and standards required for such a test. To 
insure tests work properly during development, during production and in customer laboratories, kits 
require controls and calibrators. This is particularly important for protein-based diagnostics. Controls 
for this approach may consist of cancer patient sera or potentially panels of human recombinant proteins 
for each biomarker. Because patient sera containing these biomarkers will be in short supply, the 
alternative approach of using recombinant proteins for each biomarker is much preferable. However, 
preparing such recombinant proteins as controls although feasible is clearly a substantial technical 
challenge. A more practical approach to making a feasible clinical test may be to reduce the number of 
required biomarkers. Of course, this may not be possible because reducing the number of biomarkers, 
whether they are serum autoantibodies, circulating proteins, or plasma genomic DNA targets, may result 
in a test with insufﬁ  cient accuracy to be clinically useful. Biomarker Insights 2007: 2 262
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What is Early Detection?
The clinical utility of an early detection diagnostic 
approach requires that the temporal development 
of a positive test result would signiﬁ  cantly precede 
the development of late stage cancer and therefore 
detect early stage cancer. However there is no 
established method to deﬁ  ne early detection. More-
over, what constitutes early detection may vary 
among the different types of cancer. For example, 
the early detection test of an indolent leukemia 
would have very different requirements from such 
a test for pancreatic cancer, which often is 
extremely aggressive at presentation. Different 
diagnostic settings may require either high speci-
ﬁ  city or high sensitivity. The prevalence of early 
stage disease and the costs of false positive and 
false negative diagnoses must be weighed against 
the benefits of early diagnosis. In addition, 
balancing of speciﬁ  city vs. sensitivity varies with 
the diagnostic application. For a screening cancer 
biomarker, one does not want to fail to detect indi-
viduals who have early stage but asymptomatic 
cancer. An ideal screening test would have very 
high sensitivity, identifying nearly all individuals 
with disease, but to accomplish that it may falsely 
identify many individuals who do not have cancer, 
resulting in lower specificity for the panel of 
biomarkers, and, subsequently, in unnecessary, 
invasive, medical testing. Thus it is important that 
in vitro screening tests have both high sensitivity 
and high speciﬁ  city. If test sensitivity is valued 
over test speciﬁ  city, signiﬁ  cant misclassiﬁ  cation 
in the case of low prevalence cancers may result 
in unnecessary, invasive and expensive medical 
follow-up. Conversely, valuing speciﬁ  city over 
sensitivity may fail to detect cases of cancer. In 
light of all of these factors, “a one size ﬁ  ts all” 
approach to diagnostic standards for a multianalyte 
diagnostic screening test for cancer may be impos-
sible. The balancing of speciﬁ  city and sensitivity 
may depend on the nature of the clinical follow-up 
for each cancer.
Multianalyte Cancer Diagnostics 
Numerous techniques for biomarker discovery 
have recently emerged for multianalyte diagnostics 
that are innovative and technically sound. Addi-
tional barriers will need to be surmounted for the 
transition from biomarker discovery to clinically 
effective tests. These approaches for biomarker 
discovery can be grouped into candidate biomarkers 
or undirected searches. Candidate biomarkers are 
generally identiﬁ  ed in mechanistic studies and then 
must be found in body fluids such as serum, 
plasma, saliva, sputum, or urine to be useful. An 
undirected search begins without any preconceived 
notion of the identity of the biomarkers in these 
body ﬂ  uids and usually involves high throughput 
screening technology.
Candidate Biomarkers 
A large number of cellular proteins have been 
shown to be elevated in sera from cancer patients. 
These proteins are generally referred to as “serum 
tumor markers” and can be used to monitor disease 
progression. High levels of various serum 
biomarkers, for example, CEA and CA19-9, have 
been reported in different cancers (Nozoe et al. 
2006). Intracellular proteins such as CA125 may 
be released by dying cells and detected in serum 
(Beck et al. 1998). Furthermore, serum is the store-
house for autoantibodies that are produced due to 
the activation of humoral immune response against 
tumor associated antigens, and indeed, several 
reports are based on the study of tumor inﬁ  ltrating 
lymphocytes in tumors which are the root cause 
for generation of anti-tumor immune response 
(Matsutani et al. 2004). It is well established that 
DNA levels are elevated in plasma from cancer 
patients. Plasma DNA is derived either from tumor 
apoptosis (Lichtenstein et al. 2001) or from secre-
tion of DNA by cells (Stroun et al. 2000). Saliva 
which bathes mucosa from oral cavity to larynx is 
an efﬁ  cient protective medium- an antibacterial, 
antiviral, antioxidative, etc. Tests using saliva as a 
diagnostic tool have been used in clinical and 
research areas. The presence of tumor markers, 
CA15-3 and c-erbB-2, Cathepsin-D and p53 in 
saliva of women with breast carcinoma have been 
reported (Streckfus et al. 2000). Saliva has been 
also used for oral diagnostics to detect antibodies 
to HIV (Malamud et al. 1997). Sputum samples 
from patients are clinically useful for the detection 
of lung cancer. As discussed earlier, cigarette 
smoking can lead to a series of genetic alterations 
and is the major cause of the development of lung 
cancer. Sputum cytology is a noninvasive test and 
is widely used as a diagnostic test for bronchogenic 
carcinoma (Murray et al. 2002). Urine samples 
from patients are tested for the detection of urinary 
bladder cancer. Urine has large collection of tumor 
cells and a diagnostic test for the detection of Biomarker Insights 2007: 2 263
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urothelial carcinoma can easily be achieved by 
ﬂ  ow cytometry (Cunderlikova et al. 2007). 
A number of cancer-speciﬁ  c genomic events 
have shown potential for blood-based early detec-
tion diagnostics. These cancer-speciﬁ  c genomic 
events include gene translocations (Shimazaki 
et al. 1997; Tomlins et al. 2005), point mutations 
by PCR-based sequencing (Hibi et al. 1998; 
Jeronimo et al. 2001), DNA methylation using 
sequence analysis of bisulﬁ  te treated plasma DNA 
(Belinsky et al. 2005; Esteller et al. 1999) or the 
appearance of novel RNA molecules by RT-PCR 
(Calin and Croce, 2006). These analyses are depen-
dent on the shedding of nucleic acids from tumor 
cells into the general circulation. There has been 
amazing progress towards the development of 
clinically acceptable high-throughput techniques 
for the detection of such genomic changes for the 
early detection of cancer. These techniques often 
indicate the presence or absence of a detectable 
genetic event but the diagnostic indications of any 
single cancer-specific genomic event must be 
determined individually. These approaches are 
often derived from candidate biomarkers identiﬁ  ed 
from mechanistic studies of cancer development. 
From those mechanistic studies the diagnostic 
limitations and ramiﬁ  cations of such genomics 
biomarkers may be apparent but their utility will 
have to be demonstrated in a screening setting. In 
spite of this limitation, the etiologic relationship 




An early undirected approach to the discovery of 
diagnostically useful tumor antigens referred to as 
SEREX (serological expression cloning of recom-
binant cDNA libraries of human tumors) was 
introduced by Sahin, et al. for identifying human 
tumor antigens eliciting a humoral immune 
response (Sahin et al. 1995). This technology was 
designed to isolate tumor antigens that have elicited 
high-titer IgG responses in human hosts. Brieﬂ  y, 
cDNA libraries are constructed from a fresh tumor 
specimen. The cDNA phage library is plated, 
transferred to nitrocellulose membranes which are 
then immunoscreened with autologous patient’s 
serum. This type of procedure of screening the 
cDNA expression library is quite laborious and 
requires large number of membrane ﬁ  lters blotted 
with bacteriophage plaques, which are then 
screened with sera from cancer patients, usually 
available in small quantities. This technology has 
been used for the detection of relevant tumor anti-
gens eliciting humoral immune response in many 
different cancers. Overexpression of normal gene 
products or mutation in cancer may be a major 
underlying mechanism for the immunogenicity of 
cancer antigens in cancer patients. SEREX-deﬁ  ned 
antigens, MAGE and tyrosinase, have been 
detected in melanoma patient sera (Stockert el al. 
1998). High antibody response to NY-ESO-1 has 
been detected in stage IV melanoma patients 
(Stockert el al. 1998). A classic example of muta-
tional antigen is the tumor suppressor gene p53, 
which has been identiﬁ  ed by SEREX of ovarian 
cancer (Stone et al. 2003). Several antigens for 
example, eIF-4 gamma in lung cancer (Brass et al. 
1997) and HER-2/neu in breast cancer (Scanlan 
et al. 2001), which are overexpressed and have 
mounted an immune response, have been identiﬁ  ed 
by SEREX. Although SEREX has been successful 
in identifying tumor antigens, this technology tends 
to identify antigens that were overexpressed in the 
tumor used in the discovery steps and not many 
other patients, possibly because an autologous 
patient’s serum was used for immunoscreening of 
tumor cDNA libraries. 
For high throughput antigen cloning, our group 
has developed an undirected approach using phage 
display techniques (“differential biopanning”) to 
identify the cancer antigen space within the human 
proteome (Chatterjee et al. 2006; Draghici et al. 
2005) Differential biopanning involves immuno-
screening of T7 phage tumor-derived cDNA 
libraries using a 2-step process, starting with serum 
IgGs pooled from different age-matched normal 
healthy individuals. This step helps in the removal 
of non-tumor/common antigens that bind to IgGs 
in normal sera. Next, serum IgGs from cancer 
patients are used as the bait in biopanning in order 
to enrich for clones of tumor antigens. The bound 
antigens are eluted and the resulting phage clones 
are ampliﬁ  ed for the next round of biopanning. 
Generally after four cycles of biopanning, phage 
clones are picked from multiple independent 
patients and then robotically printed on protein 
microarrays to identify circulating serum anti-
bodies produced by the cancer patient presumably 
to the cancer cells or tissue. Microarrays are 
processed with several sera obtained from cancer 
patients as well as healthy individuals. Those arrays Biomarker Insights 2007: 2 264
Tainsky et al
are then further processed with Cy3 labeled T7 
monoclonal antibody, directed against phage 
capsid protein, and Cy5 labeled goat anti-human 
IgG that recognizes the test subject’s IgG bound 
to the antigens on the arrays.
After processing, arrays are scanned and the 
ratio of anti-T7 capsid and anti-human IgG is 
determined by comparing the ﬂ  uorescence intensi-
ties in the Cy3- and Cy5-speciﬁ  c channels at each 
spot using standard image analysis programs. 
Statistical analysis is performed on the dataset of 
these dye ratios and is further validated using an 
independent set of patients and controls (Draghici 
et al. 2005; Chatterjee et al. 2006).
The top ranking antigens obtained from statistical 
analysis are readily amenable to reformatting into 
an immunoassay as a diagnostic predictor of cancer. 
The utilization of this diagnostic test in the clinic 
would be as a periodic, in vitro diagnostic screening 
immunoassay to detect the presence of cancer. This 
approach has been adopted by others in the ﬁ  eld of 
antigen biomarkers (Wang et al. 2005; Zhong et al. 
2005). The ultimate goal would be to therapeutically 
intervene via personalized immunotherapy very 
early in the development of the cancer. 
In recent years a number of serum proteomics 
approaches have sought to identify circulating 
proteins that are indicative of the presence of 
cancer in the test subject. The identiﬁ  cation of 
tumor-speciﬁ  c overexpressed proteins is often 
performed by analyzing RNA (Miura et al. 2005) 
and then testing whether those proteins are indeed 
present in the serum or plasma proteomes. Their 
study has shown that human telomerase reverse
 
transcriptase (hTERT) mRNA has higher expres-
sion in patients with hepatocellular carcinoma 
(HCC) than those with chronic liver diseases. 
Many interesting biomarkers are lost at this point 
because those upregulated RNAs do not result in 
increased proteins in body ﬂ  uids or tissues.
In an alternative approach to directly study 
protein expression in body ﬂ  uids or tumor tissues 
(Psyrri et al. 2007) a novel method of compart-
mentalized was developed for in situ protein 
analysis so as to determine the prognostic value of 
the p53 biomarker in ovarian cancer. This approach 
was based on the construction of tumor tissue 
microarray from each patient. The tissue core was 
obtained from parafﬁ  n embedded tissue blocks and 
immunohistochemical staining was performed 
(Psyrri et al. 2007) with the tissue microarray slides 
utilizing the antibody which recognizes both wild 
type and mutant p53. Their study correlated the 
higher p53 expression with better outcome for 
overall survival at 5 years. An effective diagnostic 
test will require panels of such biomarkers, 
however only a fraction will indeed be present in 
the serum of cancer patients and not healthy test 
subjects. An additional barrier to the development 
of a diagnostic test for each protein is the reformat-
ting the assay into the form of a sandwich ELISA. 
ELISA assays require one antibody (the “capture” 
antibody) that is immobilized to a solid phase 
attached to the bottom of a plate well. Antigen is 
then added which forms a complex with the capture 
antibody. The unbound products are then removed 
with a wash, and a labeled second antibody (the 
“detection” antibody) is allowed to bind to the 
antigen, thus completing the “sandwich”. The 
assay is then quantitated by measuring the amount 
of labeled second antibody bound to the matrix, 
through the use of a colorimetric substrate. Many 
otherwise good biomarkers fail at this step of 
development because of the difﬁ  culty of devel-
oping antibody pairs for a sandwich ELISA test. 
This barrier is compounded when a speciﬁ  c panel 
of protein biomarkers is needed to proceed to 
develop the ﬁ  nal test and loss of any single member 
of the panel lowers the accuracy to unacceptable 
levels. An alternative approach is to begin with 
existing pairs of antibodies to candidate biomarker 
proteins that perform well in an ELISA diagnostic 
and then determine whether any of these proteins 
are informative biomarkers for the early detection 
of cancer. However, a signiﬁ  cant barrier exists in 
the enormous range of concentrations of proteins 
in blood or other body ﬂ  uids and parallelizing such 
tests on a single platform.
A fairly recent technologic platform referred to 
as Luminex xMAP (Jones et al. 2002) has been 
reported that permits, in principle, multiplexing of 
up to 100 analytes in a single reaction and is suited 
to a wide range of applications such as proﬁ  ling 
using immunodiagnostics for candidate serum 
proteins or antibodies. The Luminex technology 
is based on color coding tiny beads, called micro-
spheres, into 100 distinct sets. Each bead set can 
be coated with a reagent speciﬁ  c to a particular 
bioassay, allowing the capture and detection of 
specific analytes from a sample. Within the 
Luminex analyzer, lasers excite the internal dyes 
that identify each microsphere particle, and also 
any reporter dye captured during the assay. Many 
readings are made on each bead set, permitting Biomarker Insights 2007: 2 265
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robust statistical analysis of the results. The bead-
based suspension array technology allows simul-
taneous analysis of antibodies with speciﬁ  cities for 
up to 100 different antigens in a single reaction. In 
an ELISA similarly formatted for multianalyte 
testing, the reactivity of one serum to several anti-
gens requires individual reactions, resulting in high 
serum consumption. While overcoming this chal-
lenge, Luminex technology is limited by the fact 
that all antibodies present in human sera can 
directly bind to the beads, with the potential of 
non-speciﬁ  c background (Waterboer et al. 2006). 
This technology has been applied to determine 
angiogenic proﬁ  les in the plasma of nude mice 
bearing human tumors (Keyes et al. 2003) and for 
the detection of increased levels of cytokines in 
cancer patients (Gorelik et al. 2005). 
A serum proteomic technology based on the 
generation of proteomic spectra of serum proteins 
using matrix-assisted laser desorption and ioniza-
tion time-of-ﬂ  ight (MALDI-TOF) and surface-
enhanced laser desorption and ionization time-of-
ﬂ  ight (SELDI-TOF) has been reported by Petricoin 
et al. for diagnosis of ovarian cancer at early stage 
(Petricoin et al. 2002). In MALDI-TOF MS, a 
small amount of specimen containing peptides and 
protein (1 µl) is dried on a target plate together
 
with a light-absorbing matrix molecule. The 
mixture of protein and matrix from surface deposits 
is vaporized by nanosecond-duration
 laser pulses. 
This results in the release of ionized protein 
molecules, which are accelerated in an electric
 ﬁ  eld 
within a vacuum. Ions with low mass/charge ratios 
(m/z)
 are accelerated to higher velocities and reach 
the detector
 before ions with a high m/z. The basic 
principle between MALDI-TOF MS and SELDI-
TOF MS is the same except in SELDI-TOF MS, 
retentate chromatography is performed directly
 on 
the surface of the target plate. The target surface 
(chip)
 is modiﬁ  ed to contain ion-exchange, hydro-
phobic, normal-phase,
 or metal chelate functional 
groups, and proteins are selectively
 captured on 
the surface depending on the protein properties
 and 
selection of binding and wash buffers. When 
Petricoin et al. applied this SELDI to a speciﬁ  c 
population of ovarian cancer patients, this tech-
nology resulted in a speciﬁ  city of 95%. Despite its 
initial, apparent success, this technology has faced 
serious concerns regarding the reproducibility of 
the data and the artifacts in sample preparation, 
storage and processing which may have biased the 
data (Diamandis, 2004). 
Although not for early detection of cancer, a 
new prognostic test that has been developed by 
scientists at the Netherlands Cancer Institute for 
evaluation of the recurrence of breast cancers is 
referred to as MammaPrint
® (van’t Veer et al. 2002; 
van de Vijver et al. 2002). MammaPrint
® is a DNA 
microarray-based in vitro diagnostic test that 
provides information about the probability of 
tumor recurrence by measuring the expression of 
70 genes previously identiﬁ  ed in a large undirected 
survey of breast cancer tissues. The MammaPrint
® 
test measures the expression level of each of these 
genes in a specimen of a woman’s surgically-
removed breast cancer tumor and then uses a 
speciﬁ  c algorithm for the generation of a score that 
determines whether the patient is considered to be 
low risk or high risk for the spread of tumor cells 
(van’t Veer et al. 2002). The study of van de Vijver 
et al. revealed that the expression proﬁ  le of 70 
genes when tested in a series of 295 consecutive 
breast cancer patients (most of them received 
adjuvant chemotherapy or hormonal therapy at the 
hospital of Netherlands Cancer Institute) performed 
best as a predictor of appearance of distant metas-
tases during ﬁ  rst ﬁ  ve years after treatment (van’t 
Veer et al. 2002). MammaPrint
® is marketed by 
Agendia BV (Amsterdam, The Netherlands) was 
the ﬁ  rst multianalyte test to obtain approval from 
FDA to predict breast cancer recurrence. Mamma-
Print
® has provided a better understanding for the 
process of approval of in vitro multianalyte diag-
nostic tests.
Translating Bioinformatics 
Techniques into Clinically 
Applicable Algorithms
There are a number of bioinformatics and biosta-
tistical techniques for performing undirected 
searches to identify a set of biomarkers that accu-
rately identify individuals with cancer and those 
without. In our laboratory we have primarily used 
neural networks to identify biomarkers that accu-
rately classify individuals as positive or negative 
for speciﬁ  c cancers, but we are also investigating 
the use of random forests. No matter what tech-
nique is used, the results must be scrupulously 
validated using cross-validation or bootstrapping 
techniques to ensure that the technique has not 
overﬁ  tted the data. Unfortunately, the accuracy 
thresholds necessary for a diagnostic test cannot 
be chosen independently of the application. The Biomarker Insights 2007: 2 266
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application depends on the disease prevalence 
and the costs of a false positive and false negative. 
For instance, if the cost of a false positive is 
minimal, high sensitivity is to be preferred. If the 
cost of a false positive is high, high speciﬁ  city is 
desirable. The exact balance depends on the 
disease, its prevalence, the costs of follow-up 
exams and the risks of not detecting the illness. 
Currently there is no federal guidance for diag-
nostic test performance for a disease in which 
there is no existing diagnostic test. The perfor-
mance characteristics must result from a test 
employing a ﬁ  xed set of analytes detecting the 
disease. Variations in the algorithms or the set of 
analytes (biomarkers) will require recertiﬁ  cation 
of the diagnostic test. 
Regulatory Issues
While the F.D.A. regulates diagnostic tests sold 
to laboratories, hospitals and physicians, it 
historically allowed tests developed by and 
performed in a single laboratory to be offered 
without F.D.A. approval. These labs are regulated 
by the federal Medicare agency under the Clinical 
Laboratory Improvement Amendments of 1988. 
However, in September 2006, the F.D.A. 
announced that it intended to require approval for 
“home brew” tests that examine multiple genes 
or proteins and use an algorithm to compute a 
result. To that end the F.D.A. issued a draft guid-
ance document for In Vitro Diagnostic Multi-
variate Index Assays (IVDMIAs). IVDMIAs are 
deﬁ  ned as “test systems that employ data derived 
in part from one or more in vitro assays, and an 
algorithm that…runs on software to generate a 
result that diagnoses a disease or condition or is 
used in the cure, mitigation, treatment, or 
prevention of disease.” The guidance document 
addresses the need for these IVDMIAs to meet 
pre-market review and post-market device 
requirements. On February 6, 2007, for the ﬁ  rst 
time, the F.D.A. cleared the marketing of an 
IVDMIA that proﬁ  les genetic activity for the 
purpose of predicting breast cancer recurrence, 
MammaPrint
®. (New York Times, 2007; U.S. 
Food and Drug Administration, 2006a; U.S. Food 
and Drug Administration, 2006b).
Assay Validation
A number of further barriers await those who 
produce a clinical diagnostic multianalyte test for 
cancer. A good sense of these barriers is evident by 
contrast to single analyte tests. There are two major 
sources of inter-test variation, the analyte and the 
assay reagents. For a single analyte test, once the 
stability characteristics in the body ﬂ  uid are estab-
lished, a standard operating procedure that can yield 
consistent results should emerge. However, if each 
member of the panel of analytes has different 
stability characteristics in the body ﬂ  uid being 
tested, then there is a greater risk of inter-analyte 
and inter-laboratory variation. Similarly, if the 
speciﬁ  c components of the test system have differing 
stability in their clinical test format, the different 
components may have varying shelf lives and these 
challenges increase geometrically with the number 
of analytes. There is also the possibility of assay 
interference among analytes. Ideally cases and 
controls should be accrued in a manner similar to 
the clinical implementation such as an asymptomatic 
population who later developed cancer but not know 
it at the time of sample donation. Such a cohort is 
the gold standard for early detection assay valida-
tion. Lastly few clinical diagnostic platforms for 
proteins are available that can accommodate 20–100 
biomarkers in a parallel assay format. While such 
technologies are undoubtedly under development, 
they will surely emerge in the diagnostic market-
place with some conservative applications rather 
than for the validation of a novel panel of cancer 
biomarkers. A natural question is how soon after 
that initial application will cancer biomarkers panels 
be evaluated? That will probably depend on the 
feasibility of widespread implementation of such 
novel platforms, the clarity of clinical and regulatory 
pathways for their use, and the ability to acquire 
sufficient reimbursement for their increased 
complexity. These new tests will require some new 
premarket pathways and postmarket requirements.
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